

Valvular Heart Disease for the Primary Care Provider

Matthew A. Cavender, MD, MPH

Associate Professor of Medicine
Director, Cardiovascular Clinical Trials
Therapeutic Area Director, UNC Clinical Research Alliance
University of North Carolina
Chapel Hill, NC



1

Disclosure

Consultant: AbbVie; Corcept; Novo Nordisk

Research Grant: Cleerly; Janssen; Massachusetts
General Hospital/PCORI; Novartis; Novo Nordisk



2

Case Presentation



School of Medicine

43-year-old physician presents to establish care for prevention.

- Known murmur "since he was a kid"
- Competitive tennis player
- No complaints

Physical Exam

- BP 126/82, pulse 74
- Normal rhythm - short, systolic murmur best heard at the LUSB
- Lungs clear
- Radial pulses normal
- No edema



3

Outline



School of Medicine

- *Approach to patient with a murmur*
- **Aortic valve disease (stenosis and regurgitation)**
- **Mitral valve regurgitation**
- **Tricuspid regurgitation**

Otto CM et al. Circulation. 2021;143: e72-e227

4

Approach to a Patient with a Murmur



School of Medicine

A structured, five-step approach:

- **History & physical exam** — identification of symptoms (if any), characterization of the murmur
- **Innocent vs. pathologic** — recognize benign flow murmurs vs. those associated with pathology
- **Dynamic auscultation** — maneuvers to narrow the differential
- **Echocardiography** — know the Class I indications for TTE
- **Further workup** — TEE, CT, or CMR as indicated

Otto CM et al. Circulation. 2021;143: e72-e227

5


Step 1: History & Physical Examination



School of Medicine

Every patient with a murmur deserves a careful history and physical exam. Key features to characterize:

- **Symptom** — presence or absence of cardiac symptoms (syncope/presyncope, SOB, chest pain, PND/orthopnea, lower extremity edema)
- **Timing in the cardiac cycle** — systolic, diastolic, or continuous
- **Location & radiation** — location gives clues to which valve involve, radiation to the neck, back, or axilla
- **Intensity** — graded 1 to 6
- **Associated findings** — ejection clicks, abnormal S2 splitting, thrills



Otto CM et al. Circulation. 2021;143: e72-e227

6

Step 1: History & Physical Examination



School of Medicine

Valve Area (APT M)	Landmark on Chest	What to Listen For
Aortic	Right upper sternal border — 2nd–3rd intercostal space, right of sternum	Aortic stenosis (crescendo-decrescendo systolic murmur); aortic regurgitation (early diastolic murmur)
Pulmonic	Left upper sternal border — 2nd–3rd intercostal space, left of sternum	Pulmonic stenosis (systolic ejection murmur); pulmonic regurgitation (Graham Steell murmur)
Erb's Point	Left middle sternal border — 3rd intercostal space, left of sternum	Aortic regurgitation (often best heard here); also useful for detecting aortic stenosis radiation
Tricuspid	Left lower sternal border — 4th–5th intercostal space, left of sternum	Tricuspid regurgitation (holosystolic murmur, increases with inspiration — Carvallo sign); tricuspid stenosis
Mitral (Apex)	Apex — 5th intercostal space, midclavicular line	Mitral regurgitation (holosystolic murmur radiating to axilla); mitral stenosis (low-pitched diastolic rumble with opening snap)

Otto CM et al. Circulation. 2021;143: e72-e227

7

Step 2: Innocent vs. Pathologic Murmurs



School of Medicine

Innocent murmur — typical features

- Grade 1–2 intensity at the left sternal border
- Midsystolic (ejection) pattern
- Normal S2 intensity and splitting
- No clicks, thrills, or added murmurs
- No increase with Valsalva or standing
- Common in high-output states (anemia, pregnancy)

Assume pathologic — always evaluate

- Diastolic murmurs — virtually always pathologic
- Most continuous murmurs (exceptions: venous hums, mammary souffles)
- Any murmur with symptoms or other abnormal findings

Otto CM et al. Circulation. 2021;143: e72-e227

8

Step 3: Dynamic Auscultation



School of Medicine

Bedside Maneuvers Change Loading Conditions and Help Narrow the Differential.

Maneuver	Physiologic effect	Murmurs that increase	Murmurs that decrease
Valsalva / Standing	↓ Preload	HCM, MVP	AS, MR, innocent murmurs
Squatting / Leg raise	↑ Preload	Most murmurs (AS, MR)	HCM, MVP
Handgrip / Arterial occlusion	↑ Afterload	MR, AR, VSD	HCM, AS
Inspiration	↑ Venous return	Right-sided (TR, PS)	—
Post-PVC / Long R-R	↑ Ventricular filling	Semilunar valves (AS, PS)	AV regurgitation unchanged

HCM, hypertrophic cardiomyopathy; MVP, mitral valve prolapse; AS, aortic stenosis; MR, mitral regurgitation; AR, aortic regurgitation; VSD, ventricular septal defect; TR, tricuspid regurgitation; PS, pulmonic stenosis.

Otto CM et al. Circulation. 2021;143: e72-e227

9

Step 4: When to Order Echocardiography



School of Medicine

Transthoracic echo (TTE) is the first-line imaging test for evaluation of cardiac murmurs. ECG can also provide important information.

Class I — recommended

- Diastolic, continuous, holosystolic, or late-systolic murmurs
- Murmurs with ejection clicks or radiation to the neck/back
- Grade ≥ 3 midsystolic murmurs
- Any murmur with heart failure, syncope, angina, thromboembolism, or suspected endocarditis

Class IIa — should consider

- Murmurs with other abnormal cardiac findings or an abnormal ECG/CXR

Class III — not recommended

- Grade ≤ 2 midsystolic murmurs confidently judged innocent by an experienced examiner

Otto CM et al. Circulation. 2021;143: e72-e227

10

Step 5: Further Workup



School of Medicine

If TTE confirms significant valvular disease, consider:

- TEE, cardiac CT, CMR, stress testing, or diagnostic catheterization — guided by the specific lesion

Key caveat

Trivial or physiologic regurgitation (mitral, tricuspid, or pulmonic) is commonly detected by color Doppler in normal hearts without murmurs — do not overinterpret it.

Otto CM et al. Circulation. 2021;143: e72-e227

11

Top 10 Take Home Messages from Valve Guidelines



School of Medicine

Disease stages should be classified on the basis of symptoms, valve anatomy, the severity of valve dysfunction, and the response of the ventricle and pulmonary circulation into Stages A, B, C, and D

Otto CM et al. Circulation. 2021;143: e72-e227

12

Valve Disease Stages



School of Medicine

Stage	Definition	Description
A	At risk	Patients with risk factors for development of VHD
B	Progressive	Patients with progressive VHD (<i>mild to moderate severity and asymptomatic</i>)
C	Asymptomatic severe	Asymptomatic patients who have the criteria for severe VHD: C1: Asymptomatic patients with severe VHD in whom the LV or RV remains compensated space C2: asymptomatic patients with severe VHD with decompensation of LV or RV
D	Symptomatic severe	Patients who have developed <u>symptoms</u> as a result of VHD

Otto CM et al. Circulation. 2021;143: e72-e227

13

Outline



School of Medicine

- Approach to patient with valve disease
- *Aortic valve disease (stenosis and regurgitation)*
- Mitral valve regurgitation
- Tricuspid regurgitation

Otto CM et al. Circulation. 2021;143: e72-e227

14

Aortic Valve Pathology




School of Medicine


**Normal
Aortic Valve**



**Bicuspid
Aortic Valve**



**Rheumatic
Aortic Valve**



**Calcific (Senile)
Aortic Valve**




Robbins, Cotran & Kumar. Pathologic basis of disease.

15

Epidemiology of Aortic Stenosis



School of Medicine




16

Natural Progression of Aortic Stenosis



School of Medicine



17

Echocardiographic Evaluation of Aortic Valve Disease



School of Medicine






Table 13. Stages of Valvular Aortic Stenosis
 Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143–e227.
 Table 13. doi:10.1161/CIR.0000000000000923.



Stage	Definition	Valve Anatomy	Valve Hemodynamics	Hemodynamic Consequences	Symptoms
A	At risk of AS	- BAV (or other congenital valve anomaly) - Aortic valve sclerosis	Aortic $V_{\max} < 2$ m/s with normal leaflet motion	None	None
B	Progressive AS	- Mild to moderate leaflet calcification/fibrosis of a bicuspid or trileaflet valve with some reduction in systolic motion or - Rheumatic valve changes with commissural fusion	Mild AS: aortic $V_{\max}$ 2.0–2.9 m/s or mean $\Delta P < 20$ mm Hg Moderate AS: aortic $V_{\max}$ 3.0–3.9 m/s or mean ΔP 20–39 mm Hg	- Early LV diastolic dysfunction may be present - Normal LVEF	None

19



Table 13. Stages of Valvular Aortic Stenosis
 Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143–e227.
 Table 13. doi:10.1161/CIR.0000000000000923.



Stage	Definition	Valve Anatomy	Valve Hemodynamics	Hemodynamic Consequences	Symptoms
C: Asymptomatic Severe AS					
C1	Asymptomatic severe AS	Severe leaflet calcification/ fibrosis or congenital stenosis with severely reduced leaflet opening	- Aortic $V_{\max} \geq 4$ m/s or mean $\Delta P \geq 40$ mm Hg - AVA typically is ≤ 1.0 cm² (or AVAi 0.6 cm²/m²) but not required to define severe AS - Very severe AS is an aortic $V_{\max} \geq 5$ m/s or mean $P \geq 60$ mm Hg	- LV diastolic dysfunction - Mild LV hypertrophy - Normal LVEF	- None - Exercise testing is reasonable to confirm symptom status
C2	Asymptomatic severe AS with LV systolic dysfunction	Severe leaflet calcification/fibrosis or congenital stenosis with severely reduced leaflet opening	- Aortic $V_{\max} \geq 4$ m/s or mean $\Delta P \geq 40$ mm Hg - AVA typically ≤ 1.0 cm² (or AVAi 0.6 cm²/m²) but not required to define severe AS	LVEF $< 50\%$	None

20



Table 13. Stages of Valvular Aortic Stenosis
 Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143–e227.
 Table 13. doi:10.1161/CIR.0000000000000923.



Stage	Definition	Valve Anatomy	Valve Hemodynamics	Hemodynamic Consequences	Symptoms
D: Symptomatic severe AS					
D1	Symptomatic severe high-gradient AS	Severe leaflet calcification/fibrosis or congenital stenosis with severely reduced leaflet opening	- Aortic $V_{\max} \geq 4$ m/s or mean $\Delta P \geq 40$ mm Hg - AVA typically ≤ 1.0 cm² (or $AVA_i \leq 0.6$ cm²/m²) but may be larger with mixed AS/AR	- LV diastolic dysfunction - LV hypertrophy - Pulmonary hypertension may be present	- Exertional dyspnea, decreased exercise tolerance, or HF - Exertional angina - Exertional syncope or presyncope
D2	Symptomatic severe low-flow, low-gradient AS with reduced LVEF	Severe leaflet calcification/fibrosis with severely reduced leaflet motion	- AVA ≤ 1.0 cm² with resting aortic $V_{\max} < 4$ m/s or mean $\Delta P < 40$ mm Hg - Dobutamine stress echocardiography shows AVA < 1.0 cm² with $V_{\max} \geq 4$ m/s at any flow rate	- LV diastolic dysfunction - LV hypertrophy - LVEF $< 50\%$	- HF - Angina - Syncope or presyncope

21



Table 13. Stages of Valvular Aortic Stenosis
 Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143–e227.
 Table 13. doi:10.1161/CIR.0000000000000923.




Stage	Definition	Valve Anatomy	Valve Hemodynamics	Hemodynamic Consequences	Symptoms
D: Symptomatic severe AS					
D3	Symptomatic severe low-gradient AS with normal LVEF or paradoxical low-flow severe AS	Severe leaflet calcification/fibrosis with severely reduced leaflet motion	- AVA ≤ 1.0 cm² (indexed AVA ≤ 0.6 cm²/m²) with an aortic $V_{\max} < 4$ m/s or mean $\Delta P < 40$ mm Hg - AND - Stroke volume index < 35 mL/m² - Measured when patient is normotensive (systolic blood pressure < 140 mm Hg)	- Increased LV relative wall thickness - Small LV chamber with low stroke volume - Restrictive diastolic filling - LVEF $\geq 50\%$	- HF - Angina - Syncope or presyncope

22

Natural Progression of Aortic Stenosis



School of Medicine



Otto CM, et al. *Circulation*. 95: 2262, 1997
 Rosenhek R., et al. *Circulation*. 121:151, 2010

23



Timing of Intervention of AS



COR	LOE	Recommendations
1	A	1. In adults with severe high-gradient AS (Stage D1) and symptoms of exertional dyspnea, HF, angina, syncope, or presyncope by history or on exercise testing, AVR is indicated.
1	B-NR	2. In asymptomatic patients with severe AS and an LVEF <50% (Stage C2), AVR is indicated.
1	B-NR	3. In asymptomatic patients with severe AS (Stage C1) who are undergoing cardiac surgery for other indications, AVR is indicated.

Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. *Circulation*. 2021;143:e227. doi:10.1161/CIR.0000000000000923.

24




Timing of Intervention of AS



COR	LOE	Recommendations
1	B-NR	4. In symptomatic patients with low-flow, low-gradient severe AS with reduced LVEF (Stage D2), AVR is recommended.
1	B-NR	5. In symptomatic patients with low-flow, low-gradient severe AS with normal LVEF (Stage D3), AVR is recommended if AS is the most likely cause of symptoms.

Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. *Circulation*. 2021;143:e227. doi:10.1161/CIR.0000000000000923.

25



26

ARS Question #1


Aortic Valve Replacement Should Be Considered for All of the Following Except:

- A. Asymptomatic, Aortic Valve Velocity >5 m/s
- B. Symptomatic, Aortic Valve Velocity >4 m/s
- C. Symptomatic, Aortic Valve Velocity >3.0 m/s
- D. Asymptomatic, Aortic Valve Velocity <4 m/s

Treatment of Aortic Stenosis



School of Medicine



Otto CM, et al. 2020 ACC/AHA
Guideline for the Management of
Patients With Valvular Heart Disease.
Circulation. 2021;143:e227.
doi:10.1161/CIR.0000000000000923.

Mechanical vs Bioprosthetic Valve




School of Medicine

Feature	Mechanical Valve	Bioprosthetic Valve
Durability	Designed to last a lifetime	Structural deterioration over time (15-yr reoperation risk: ~22% at age 50, ~30% at age 40, ~50% at age 20)
Anticoagulation	Lifelong VKA required (INR 2.0–3.0 for aortic; 2.5–3.5 for mitral)	Not required unless other indication (e.g., AF)
Lifestyle impact	Dietary restrictions, medication interactions, activity limitations, frequent INR monitoring	Fewer restrictions; no routine INR monitoring after initial period
Pregnancy	VKA therapy poses teratogenic risk; complex anticoagulation management during pregnancy	Preferred in women desiring future pregnancy (avoids VKA in pregnancy)
Valve-in-valve option	Not applicable	Transcatheter valve-in-valve (ViV) replacement available
Hemodynamics	Smaller effective orifice area in smaller sizes	TAVI bioprostheses may offer larger effective orifice areas in smaller sizes (less patient–prosthesis mismatch)

29

ACC/AHA Guidelines Mechanical vs. Bioprosthetic



30

Choice of Intervention: Mechanical Versus Bioprosthetic AVR




COR	LOE	Recommendations
1	C-EO	1. In patients with an indication for AVR, the choice of prosthetic valve should be based on a shared decision-making process that accounts for the patient's values and preferences and includes discussion of the indications for and risks of anticoagulant therapy and the potential need for and risks associated with valve reintervention.
1	C-EO	2. For patients of any age requiring AVR for whom VKA anticoagulant therapy is contraindicated, cannot be managed appropriately, or is not desired, a bioprosthetic AVR is recommended.
2a	B-R	3. For patients <50 years of age who do not have a contraindication to anticoagulation and require AVR, it is reasonable to choose a mechanical aortic prosthesis over a bioprosthetic valve.

Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. *Circulation*. 2021;143:e72–e227. doi:10.1161/CIR.0000000000000923.


31

PARTNER Study Design



32


All-Cause Mortality (ITT) Crossover Patients Censored at Crossover



* In an age and gender matched US population without comorbidities, the mortality at 5 years is 40.5%.

33


Outcomes in Low Risk Patients n=1000 Patients Randomized to SAVR or TAVR



N Engl J Med 2019; 380:1695-1705

34

Outcomes in Low Risk Patients n=1000 Patients Randomized to SAVR or TAVR



N Engl J Med 2019; 380:1695-1705

35

Outcomes with Aortic Valve Replacement in Low Risk Surgical Patients




School of Medicine

Outcome	SAPIEN 3 (PARTNER 3)	Evolut (Evolut Low Risk)	SAVR (PARTNER 3 / Evolut)
30-day mortality	0.4%	0.5%	1.1–1.3%
30-day all stroke	0.6%	3.4%	2.4–3.4%
30-day life-threatening/major bleeding	~3.6%	2.4%	7.5%
30-day new pacemaker	6.6%	17.4%	4.1–6.1%
1-year mortality	1.0%	2.4%	2.5–3.0%
1-year all stroke	2.0%	4.1%	3.6–4.3%
1-year life-threatening/disabling bleeding	~5%	3.2%	8.9%
1-year new pacemaker	~7.3%	19.4%	6.7–7.0%


N Engl J Med 2019;380:1695-1705 *J Am Coll Cardiol* 2021; 77: 1149-1161
N Engl J Med 2019;380:1706-1715 *N Engl J Med* 2023;389:1949-1960

36

Matthew Cavender, MD
Valvular Heart Disease for the Primary Care Provider



37




38

Current Guideline Recommendations for Life-Cycle Management of Severe Aortic Stenosis



J Am Coll Cardiol 2023;82:721–734



39

ARS Question #2

As Compared to Surgery, Transcatheter Aortic Valve Replacement Results in All of the Following Except:


- A. Lower morbidity and mortality
- B. Lower rates of stroke
- C. Shorter length of stay, higher quality of life (at 30 days)
- D. Lower rates of pacemaker

40

Echocardiogram of Aortic Insufficiency



School of Medicine




41

Echocardiogram of Aortic Insufficiency



School of Medicine



COR	LO	Recommendations
1	E B- NR	In asymptomatic patients with chronic AR (Stages B and C), treatment of hypertension (systolic blood pressure >140 mm Hg) is recommended.
1	B- NR	In patients with severe AR who have symptoms and/or LV systolic dysfunction (Stages C2 and D) but a prohibitive surgical risk, GDMT for reduced LVEF with ACE inhibitors, ARBs, and/or sacubitril/valsartan is recommended.


Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. *Circulation*. 2021;143–e227. doi:10.1161/CIR.0000000000000923.

42

Trilogy Valve for Aortic Insufficiency




School of Medicine




Alignment

- Aligns THV with native cusps



Positioning/Anchoring

- Locators “clip” onto native leaflets forming a natural seal and stable securement



Deployment

- Large open cells provide access to low coronaries
- Flared sealing ring conforms to annulus

Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. *Circulation*. 2021;143:e227. doi:10.1161/CIR.0000000000000923.

43

Outline



School of Medicine

- Approach to patient with valve disease
- Aortic valve disease (stenosis and regurgitation)
- Mitral valve regurgitation*
- Tricuspid regurgitation

Otto CM et al. *Circulation*. 2021;143: e72-e227



44

Primary Mitral Regurgitation



School of Medicine

Carpentier Classification of Mitral Valve Regurgitation



Mori, Shivkumar *Atlas of Cardiac Anatomy*, Digital Edition 2022
Valvular Disorders. Practical Cardiovascular Medicine 2e

45



Intervention for Patients with Chronic Primary MR



COR	LOE	Recommendations
1	B-NR	1. In symptomatic patients with severe primary MR (Stage D), mitral valve intervention is recommended irrespective of LV systolic function.
1	B-NR	2. In asymptomatic patients with severe primary MR and LV systolic dysfunction (LVEF ≤60%, LVESD ≥40 mm) (Stage C2), mitral valve surgery is recommended.
1	B-NR	3. In patients with severe primary MR for whom surgery is indicated, mitral valve repair is recommended in preference to mitral valve replacement when the anatomic cause of MR is degenerative disease, if a successful and durable repair is possible.
2a	B-NR	4. In asymptomatic patients with severe primary MR and normal LV systolic function (LVEF ≥60% and LVESD ≤40 mm) (Stage C1), mitral valve repair is reasonable when the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality rate of <1%, when it can be performed at a Primary or Comprehensive Valve Center.


Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. *Circulation*. 2021;143–e227. doi:10.1161/CIR.0000000000000923.

46

Functional Mitral Regurgitation Is a Problem with the Left Ventricle



School of Medicine



Tethered posterior leaflet seen with ischemic heart disease

Dilated cardiomyopathy resulting in a central jet due to lateral and apical displacement of the papillary muscles

47



Medical Therapy for Secondary MR




COR	LOE	Recommendations
1	A	1. Patients with chronic severe secondary MR (Stages C and D) and HF with reduced LVEF should receive standard GDMT for HF, including ACE inhibitors, ARBs, beta blockers, aldosterone antagonists, and/or sacubitril/valsartan, and biventricular pacing as indicated.
1	C-EO	2. In patients with chronic severe secondary MR and HF with reduced LVEF, a cardiologist expert in the management of patients with HF and LV systolic dysfunction should be the primary MDT member responsible for implementing and monitoring optimal GDMT.

Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. *Circulation*. 2021;143:e227. doi:10.1161/CIR.0000000000000923.

48

Matthew Cavender, MD
Valvular Heart Disease for the Primary Care Provider




49

Edge to Edge Repair of Mitral Valve



School of Medicine



N Engl J Med 2011;364:1395-406


50

State of the Union – Mitral Valve Interventions



School of Medicine

Centers for Medicare and Medicaid Services data (2012-2019), 53,117 mitral valve interventions




Rates of M-TEER are increasing while rates of surgical repair and replacement are declining

Chikwe J. et al, J Thorac Cardiovasc Surg 2025;169:80-8

51

Edwards Sapien M3 (29mm)



52

Outline




School of Medicine

- Approach to patient with valve disease
- Aortic valve disease (stenosis and regurgitation)
- Mitral valve regurgitation
- *Tricuspid regurgitation*

Otto CM et al. Circulation. 2021;143: e72-e227

53

Tricuspid Valve Regurgitation Algorithm




Salter et al. JAMA Cardiol 2026;11;(1):98-10


54

EVOQUE Transcatheter Tricuspid Valve Replacement System

EVOQUE Valve



Available in three sizes



EVOQUE Delivery System



CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use.

55

Summary and Conclusions



School of Medicine

- Every murmur needs a focused H&P.** Characterize timing, intensity, location, and radiation, and screen for symptoms (syncope, dyspnea, angina).
- Diastolic and continuous murmurs are almost always pathologic.** Innocent murmurs are soft (grade 1–2), midsystolic, with a normal S2 and no added sounds.
- TTE is the first-line test.** Order it for any diastolic/continuous murmur, a loud or symptomatic systolic murmur, or abnormal ECG/exam findings.
- Don't overinterpret trivial/mild regurgitation.** trace mitral, tricuspid, or pulmonic flow on color Doppler is common in normal hearts.
- Stage disease.** Use symptoms, valve anatomy, severity of dysfunction, and ventricular/pulmonary response; correlate exam with imaging.
- Refer aortic stenosis early.** Symptom onset (angina, syncope, HF) marks a steep rise in mortality; severe AS may warrant referral before symptoms.
- TAVR is now indicated for all levels of risk (including low-risk).** Refer severe AS to a valve team for shared decision-making.
- Valve choice is a shared decision.** Mechanical = durable but needs lifelong anticoagulation (younger); bioprosthetic = no long-term anticoagulation (older).
- In severe primary MR, refer before LV dysfunction.** TEER is an option at high surgical risk; secondary MR is an LV problem so optimize GDMT first.
- Don't forget about the tricuspid valve.** Now have better options for severe TR (including transcatheter).

56